BioChem C785 - WGU - Module 2 - all questions Deedra's dad has Alzheimer's Disease (AD) which is caused by a change in protein structure - CORRECT ANSWER True Alzheimer's disease is caused by aggregation of the Amyloid beta peptide and tangle formation by the tau protein. What kinds of amino acids are likely to drive the formation of these protein aggregates? - CORRECT ANSWER hydrophobic After learning about Alzheimer's disease and one of the drugs used in its treatment, what other drug design strategies could you use to offer treatment for AD? - CORRECT ANSWER 1. Drugs that break up the amyloid plaques
- Drugs that block the production of amyloid beta peptide
- drugs that inhibits the aggregation of protein structures 1 / 2
A substrate binds to an enzyme at a specific site is referred to as - CORRECT ANSWER an active site You are in charge of designing a drug that inhibits the activity of a specific enzyme. An important criteria for the drug selection is to ensure that the drug is directly in competition with the original substrate when binding to the active site of the enzyme. What inhibitor would be an ideal choice? - CORRECT ANSWER A competitive inhibitor
These factors can affect the protein folding and activity of an enzyme: -
CORRECT ANSWER 1. pH
- Heat
- Reducing agents
- / 2
One way a cell can avoid overproduction of a molecule is by using a particular type of inhibition in which the molecule itself acts as an inhibitor for an enzyme in its production pathway. This type of regulation is known as feedback inhibition - CORRECT ANSWER True